Joincare Vice President Tang Tingke Visits MoMed Biotech, Forging New Consensus on Deeper AI-Driven Drug Development Collaboration
Following previous exchanges between MoMed Biotech and Joincare Pharmaceutical Group Industry Co., Ltd. in Shenzhen, Tang Tingke, Vice President of Joincare, visited MoMed Biotech in April 2026. He held in-depth discussions with Bai Chen, Chairman of MoMed, and the core team on topics including AI-powered drug discovery platforms, tackling difficult drug targets, and novel molecular design.
。
On April 17, 2026, Tang Tingke, Vice President of Joincare Pharmaceutical Group Industry Co., Ltd. (hereinafter referred to as "Joincare"), visited MoMed (Hangzhou) Biotechnology Co., Ltd. (hereinafter referred to as "MoMed Biotech"). Bai Chen, Chairman of MoMed Biotech, along with the core R&D team, warmly received him and accompanied him on a tour of the company's key R&D facilities and infrastructure.
During the meeting, Chairman Bai Chen focused on the planning and progress of the company's key drug pipelines. Building on his previous introduction of the AI R&D platform, he further analyzed the advantages and development strategies of the current pipelines and proposed several collaborative ideas, hoping to combine the strengths of both parties and deepen R&D cooperation.
Vice President Tang Tingke spoke highly of MoMed Biotech's technological capabilities. He noted that Joincare has long focused on the application of cutting-edge technologies in the pharmaceutical industry, and that MoMed Biotech's technical expertise and platform capabilities in AI-driven drug development closely align with Joincare's practical needs in innovative drug R&D.
This visit marked another significant interaction following MoMed Biotech's earlier trip to Shenzhen to meet with Joincare. Both parties reached a high level of consensus on technological collaboration and joint project research. Mr. Tang indicated that Joincare would actively promote the docking and implementation of specific target projects moving forward, aiming to establish a sustainable cooperation mechanism.
At the conclusion of the meeting, both sides expressed a strong desire to further deepen their collaboration. This visit not only enhanced mutual understanding and trust but also laid a solid foundation for future in-depth cooperation in innovative drug R&D and technology translation. It is believed that through joint efforts and an "AI + full industry chain" cooperation model, both parties will overcome challenges related to difficult drug targets and inject new momentum into China's pharmaceutical innovation.
END
Joincare Pharmaceutical Group Industry Co., Ltd. (Stock code: 600380), founded in 1992 and headquartered in Shenzhen, is an innovative, research-driven comprehensive pharmaceutical group. Listed on the Shanghai Stock Exchange in 2001, the company owns two listed subsidiaries — Joincare and Livzon Pharmaceutical — along with over 20 major holding subsidiaries. Its business spans chemical preparations, active pharmaceutical ingredients (APIs), and traditional Chinese medicines, with a focus on respiratory diseases and anti-infectives. Joincare adheres to an innovation-driven development strategy, leveraging technological innovation as its foundation and deep AI application as its core engine. In 2018, the company ranked 10th on the "Top 100 Chinese Chemical Pharmaceutical Enterprises" list, and in 2019, it ranked 151st among Guangdong's Top 500 Enterprises and 52nd among Guangdong's Top 100 Private Enterprises.
MoMed Biotech (MOMED Biotech, www.momed.com.cn) is the world's first biotechnology company driven by mechanistic studies of drug targets, combining advanced artificial intelligence technologies to drive innovative drug discovery. MoMed employs Nobel Prize-winning computational biology methods to investigate the working mechanisms of target proteins, achieving a methodological leap in AI data generation. The company's MechGen drug discovery platform integrates industry-leading computational biology and AI-based drug design technologies, offering a range of preclinical drug discovery services to the industry.
分享:
Hot News
- 2024-10-31
- 2024-11-22
- 2025-01-16
-
2025-01-17
MoMed Biotech's Moments on CCTV! Catch the Wonderful Highlights in Advance!